Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Shenzhen Edge Medical (精锋医疗) IPO Trading

Shenzhen Edge Medical (精锋医疗) Pre-IPO: Fast Follower, Competition Is Intense

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Shenzhen Edge Medical / Equity Capital Markets

<ul>
<li>Shenzhen Edge Medical, a China-based surgical robotic company, launched its IPO to raise at least USD 154 million via a Hong Kong listing.</li>
<li>In this note, we look at the deal terms and provide a valuation for the company.</li>
<li>We think the deal is well timed when its comparable peer performed well.</li>
</ul>


Shenzhen Edge Medical, a China-based surgical robotic company, launched its IPO to raise at least USD 154 million via a Hong Kong listing.
In this note, we look at the deal terms and provide a valuation for the company.
We think the deal is well timed when its comparable peer performed well.


Shenzhen Edge Medical (精锋医疗) IPO: Well-Timed Launch Supports Valuation